Holen Sie sich die Stockscreener-App
5.99
0.17%
-0.010
Handel nachbörslich:
6.10
0.11
+1.84%
Schlusskurs vom Vortag:
$6.00
Offen:
$6.03
24-Stunden-Volumen:
7,841
Relative Volume:
0.35
Marktkapitalisierung:
$27.02M
Einnahmen:
$85.53M
Nettoeinkommen (Verlust:
$-9.78M
KGV:
-2.7287
EPS:
-2.1952
Netto-Cashflow:
$1.28M
1W Leistung:
-1.96%
1M Leistung:
-0.83%
6M Leistung:
+1.30%
1J Leistung:
+6.07%
1-Tages-Spanne:
$5.9501
$6.24
1-Wochen-Bereich:
$5.9501
$6.28
52-Wochen-Spanne:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Firmenname
Harvard Bioscience Inc
Sektor
Telefon
(508) 893-8999
Adresse
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
5.99 | 27.06M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
356.83 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
158.92 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.70 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.28 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
203.08 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | Eingeleitet | Northland Capital | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | Herabstufung | Janney | Buy → Neutral |
| 2018-01-24 | Bestätigt | Janney | Buy |
| 2018-01-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-11-17 | Eingeleitet | Singular Research | Buy |
| 2015-07-28 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Harvard Bioscience Inc Aktie (HBIO) Neueste Nachrichten
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HBIO|Harvard Bioscience Inc|Price:6.000|Chg%:-0.190 - TradingKey
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience, Inc. Revenue Breakdown – MUN:HBI0 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LS:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – NASDAQ:HBIO - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LSX:A423J5 - TradingView
HBIO Q2'26 Earnings: revenue estimate is 21.45M USD - TradingView
HBIO Stock Price, Quote & Chart - ChartMill
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de
Harvard Bioscience focuses on lab equipment growth - Ad-hoc-news.de
Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume TradingBollinger Walk - dars.gov.et
Harvard Bioscience | SD: Specialized disclosure report - Moomoo
Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView
HBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to earnings forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to book forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Enterprise value to EBITDA forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience (HBIO) Slips Slightly, Holding Above Support at $5.71Quality Factor - dars.gov.et
Harvard Bioscience holds key trading range, shares between support and resistance - AD HOC NEWS
HBIO News | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience Inc (HBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 RSUs in new grant - Stock Titan
Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs - Stock Titan
HBIO Q1 2026 Earnings: Significant EPS Beat Drives Positive Stock ReactionMid-Term Outlook - dars.gov.et
Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results - Moomoo
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors - TipRanks
Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases - Stock Titan
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
Harvard Bioscience (HBIO) Edges Lower Amid Modest Selling Pressure – Key Support Levels in FocusOn Balance Volume - dars.gov.et
HBIOHarvard Bioscience Inc Website Traffic and Mobile Apps Usage - Finviz
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
QTEX Stock Price and Chart — NASDAQ:QTEX - TradingView
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
HBIO: Operational consolidation, innovation, and recurring revenue drive margin and growth targets - TradingView
Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha
Finanzdaten der Harvard Bioscience Inc-Aktie (HBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.62%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):